9 completed, 6 unknown, 2 not yet recruiting, 2 recruiting. 21 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 21 | Completed 9, Unknown 6, Not yet recruiting 2, Recruiting 2, Terminated 1, Withdrawn 1 |
Follow Overactive Bladder Syndrome: new trials by email Literature Review of Overactive Bladder Syndrome trials Research Report on Overactive Bladder Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children Urgent PC - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Not yet recruiting | Chi Dang Hornik | 50 | 2027-04-01 | 2026-06-17 |
| Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study Tadalafil 5 mg, Solifenacin 5mg - Overactive Bladder (OAB), Overactive Bladder Syndrome | Phase 4 | Recruiting | Mansoura University | 480 | 2025-09-01 | 2026-02-18 |
| Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections Lidocaine 2% without vessel constrictor - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Not yet recruiting | University of Louisville | 36 | 2024-12-01 | 2024-11-19 |
| Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women vaginal 17 beta-estradiol, Placebo, Behavioral modifications - Lower Urinary Tract Symptoms, Female Genitourinary Disease | Phase 4 | Completed | Mahidol University | 86 | 2024-04-08 | 2025-04-20 |
| Comparing Treatments for Refractory Overactive Bladder: Bladder Denervation vs Botulinum Toxin Injections Selective Bladder Denervation via Radiofrequency Ablation, Intravesical Onabotulinum Toxin A Injection - Overactive Bladder Syndrome, Refractory Overactive Bladder | Phase 4 | Completed | Bagcilar Training and Research Hospital | 60 | 2023-02-01 | 2025-02-19 |
| Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection Single-Dose Antibiotic, Multi-Dose Antibiotic - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Completed | The Cleveland Clinic | 100 | 2022-12-06 | 2024-01-02 |
| Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome Vaginal estrogen, Mirabegron 50 MG [Myrbetriq] - Overactive Bladder Syndrome | Phase 4 | Recruiting | Walter Reed National Military Medical Center | 152 | 2022-10-01 | 2024-08-19 |
| Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial OnabotulinumtoxinA 100 UNT [Botox] - Overactive Bladder, Urinary Urge Incontinence | Phase 4 | Completed | University of California, Irvine | 116 | 2022-05-01 | 2026-02-25 |
| Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1 Darifenacin, Neuromodulation - Sacral nerve stimulation - HTLV-1, Overactive Bladder Syndrome | Phase 4 | Completed | Hospital Universitário Professor Edgard Santos | 42 | 2022-03-16 | 2024-10-01 |
| Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial OnabotulinumtoxinA - Overactive Bladder Syndrome, Overactive Bladder | Phase 4 | Unknown | Augusta University | 100 | 2022-01-01 | 2021-12-15 |
| Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial mirabegron, TTNS - Overactive Bladder Syndrome | Phase 4 | Unknown | Taipei Veterans General Hospital, Taiwan | 180 | 2021-11-10 | 2022-01-12 |
| Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder mirabegron, oxybutynin, tolterodine, solifenacin - Sjogren's Syndrome, Overactive Bladder Syndrome | Phase 4 | Unknown | China Medical University Hospital | 50 | 2021-03-23 | 2021-08-10 |
| Minimizing Pain During Office Intradetrussor Botox Injection Bicarbonate protocol, Standard protocol - Overactive Bladder, Overactive Detrusor | Phase 4 | Completed | Boston Urogynecology Associates | 85 | 2020-08-15 | 2025-03-06 |
| Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome Tolterodine Tartrate 4 MG, Continuous positive airway pressure therapy (CPAP) - Overactive Bladder, Obstructive Sleep Apnea | Phase 4 | Completed | Yuzuncu Yil University | 60 | 2020-06-01 | 2022-02-22 |
| Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome Mirabegron 25mg - Overactive Bladder Syndrome | Phase 4 | Withdrawn | Far Eastern Memorial Hospital | 2018-12-24 | 2019-03-07 | |
| Oral vs Intravesical Analgesia for Office Bladder Botox Injections Phenazopyridine, Lidocaine 2% Injectable Solution - Overactive Bladder Syndrome, Urge Incontinence | Phase 4 | Unknown | Women and Infants Hospital of Rhode Island | 110 | 2018-11-01 | 2020-05-29 |
| OnabotulinumtoxinA Bladder Injection Study OnabotulinumtoxinA 100Unit Injection - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Terminated | Corewell Health East | 6 | 2018-08-08 | 2022-02-10 |
| Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing daytime dosing of mirabegron, nighttime dosing of mirabegron - Overactive Bladder Syndrome | Phase 4 | Unknown | Far Eastern Memorial Hospital | 120 | 2017-08-01 | 2023-03-29 |
| Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes solifenacin, mirabegron - Overactive Bladder Syndrome | Phase 4 | Completed | National Taiwan University Hospital | 113 | 2015-09-08 | 2023-03-28 |
| Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients Solifenacin for 12 weeks, Solifenacin for 24 weeks - Overactive Bladder Syndrome | Phase 4 | Unknown | National Taiwan University Hospital | 200 | 2013-05-01 | 2015-07-07 |
Showing 20 of 21. Sign in to see all of them.
Urinary Bladder, Overactive (14) · Urinary Incontinence, Urge (7) · Urinary Incontinence (3) · Female Urogenital Diseases (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lower Urinary Tract Symptoms (1) · Nocturia (1) · Sjogren's Syndrome (1) · Sleep Apnea, Obstructive (1) · Spasm (1) · Urinary Bladder Diseases (1) · Urinary Bladder, Neurogenic (1) · Urinary Incontinence, Stress (1) · Urologic Diseases (1)
Female Urogenital Diseases and Pregnancy Complications (14) · Male Urogenital Diseases (14) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (14) · Urogenital Diseases (14) · Urological Manifestations (14) · Female Urogenital Diseases (13) · Lower Urinary Tract Symptoms (13) · Urinary Bladder Diseases (13) · Urologic Diseases (13) · Urination Disorders (9) · Urinary Incontinence (6) · Nervous System Diseases (4) · Neurologic Manifestations (2) · Apnea (1)
Solifenacin Succinate (5) · mirabegron (5) · Botulinum Toxins, Type A (3) · Estradiol (2) · Lidocaine (2) · Tolterodine Tartrate (2) · AIEOP acute lymphoblastic leukemia protocol (1) · Anti-Bacterial Agents (1) · Antibiotic Prophylaxis (1) · Phenazopyridine (1) · Tadalafil (1) · darifenacin (1) · onabotulinum toxin A (1) · oxybutynin (1) · stearic acid (1)
Far Eastern Memorial Hospital (2) · National Taiwan University Hospital (2) · Augusta University (1) · Bagcilar Training and Research Hospital (1) · Boston Urogynecology Associates (1) · Chi Dang Hornik (1) · China Medical University Hospital (1) · Corewell Health East (1) · Hospital Universitário Professor Edgard Santos (1) · Loyola University (1) · Mahidol University (1) · Mansoura University (1) · Taipei Veterans General Hospital, Taiwan (1) · The Cleveland Clinic (1) · University of California, Irvine (1)
United States (8) · Taiwan (6) · Turkey (Türkiye) (2) · Brazil (1) · Egypt (1) · Thailand (1)
Ahana Gaurav (1) · Ahmed A Shokeir, professor of urology (1) · Carly Crowder, MD (1) · Chi Hornik (1) · Chih-Chieh Lin, MD/Phd (1) · Christopher W Heuer, DO (1) · Emily Grandprey, DO (1) · Emily Lluch (1) · Emily Slopnick, MD (1) · Felicia Lane, MD (1) · Ho-Hsiung Lin, MD, PhD (1) · Jennifer Lanzer, MD (1) · Larry Sirls, MD (1) · Lauren E Stewart, MD (1) · Mary P FitzGerald, MD (1)
PMID 26724409, PMID 28714288, PMID 29264126, PMID 34225282, PMID 35580634, PMID 37160401, PMID 40025238, PMID 40841399